Cytokinetics, Incorporated— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.42B
↑+1.6% +$23Mvs FY2024
Total Liabilities
$2.08B
↑+35.6% +$547Mvs FY2024
Cash
$123M
↑+29.2% +$28Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.42B | $1.40B |
| Current Assets | $917M | $1.11B |
| Cash | $123M | $95M |
| ST Investments | $0 | $0 |
| Receivables | $18M | $17M |
| Inventory | $0 | $0 |
| Other Current | $777M | $996M |
| Non-Current Assets | $508M | $294M |
| PPE | $79M | $66M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $428M | $228M |
| Total Liab+Eq | $1.42B | $1.40B |
| Current Liab. | $202M | $180M |
| Accounts Payable | $22M | $20M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $2M | $52M |
| Other CL | $179M | $107M |
| Non-Current Liab. | $1.88B | $1.36B |
| Long-Term Debt | $246M | $93M |
| Other LT Liab. | $1.64B | $1.26B |
| Equity | $-660M | $-135M |
| Retained Earnings | $3.49B | $2.70B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · CYTK · Comparing FY2025 vs FY2024